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cially since all patients were first treated
with placebo and then with intranasal
DDAVP. Beladi-Mousavi et al. used a
rather liberal definition of dialysis hy-
potension: a fall in systolic blood pressure
>10mmHg. Although there is no stan-
dardized definition of intradialytic hy-
potension, recent guidelines propose a
more strict definition: a decrease in sys-
tolic blood pressure >_20mmHg or a de-
crease in MAP by 10mmHg in combina-
tion with a clinical event and the need for
a nursing intervention.3
Notably, there are alternative vasopressin-
related measures for the prevention of
dialysis hypotension. Recently, we
showed that hemodialysis with the
biofeedback system Hemocontrol is asso-
ciated with a significant increase of plas-
ma vasopressin levels, whereas vaso-
pressin levels did not change during
conventional hemodialysis.4 Hemocontrol
is a technique in which ultrafiltration rate
and dialysate conductivity are continuous-
ly adjusted in response to blood volume
changes. The augmented vasopressin re-
lease early during Hemocontrol hemodial-
ysis is likely caused by a higher initial
plasma sodium concentration and ultrafil-
tration rate.
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With interest, we read the article by Bela-
di-Mousavi et al.1 on the effect of in-
tranasal DDAVP (Desmopressin) for the
prevention of dialysis hypotension. The
authors showed that, compared with
placebo, intranasally administered
DDAVP was associated with a significant
decrease in the incidence of intradialytic
hypotension episodes and higher postdial-
ysis mean arterial blood pressures in 17
hypotension-prone patients. This observa-
tion adds evidence to the efficacy of vaso-
pressin analogues for the prevention of
dialysis hypotension following the study
of Lindberg et al. showing that intranasal
lysine-vasopressin increased intradialytic
blood pressure in 6 patients with refracto-
ry dialysis hypotension.2 However, in our
opinion, important questions should be
answered before intranasal vasopressin
analogues can be recommended for the
prevention of dialysis hypotension. First,
the optimal timing and dosage of in-
tranasal Desmopressin and vasopressin
administration must be determined.
Therefore, it is important to know which
dosage of DDAVP spray (2 puffs) Beladi-
Mousavi et al. exactly used in their study.
Second, the safety of repetitive intranasal
administration of vasopressin analogues
should be studied. Did Beladi-Mousavi et
al. observe side effects of DDAVP treat-
ment? Finally, future studies should com-
pare the efficacy and safety profile of this
treatment with other established measures
for the prevention of dialysis hypotension,
like cold dialysate and Midrodrine admin-
istration.
We have some methodological comments
on the study by Beladi-Mousavi et al. The
authors did not state whether the placebo
nasal spray (distilled water) was indistin-
guishable from the intranasal DDAVP
spray. This is relevant to ensure that this
was indeed a double-blind study, espe-
release is enhanced by the Hemocontrol
biofeedback system and could contribute
to better haemodynamic stability during
haemodialysis. Nephrol Dial Transplant
2012 Feb 7. [Epub ahead of print].
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En relación con el Documento de Con-
senso publicado en esta revista el pasa-
do mes de febrero sobre el diagnóstico
y tratamiento de la nefritis lúpica
(NL)1, deseo felicitar al grupo de traba-
jo por la exquisita labor realizada, a
partir de la cual esperamos optimizar el
tratamiento de pacientes con esta pato-
logía. De su lectura me han surgido dos
reflexiones.
1. Houssiau2 refiere, en un editorial ane-
xo a la publicación del estudio
ALMS3, que, entre los pacientes que
recibieron tratamiento de manteni-
miento con micofenolato (MMF), los
que previamente habían recibido ci-
clofosfamida (CF) en inducción obtu-
vieron mejores resultados en la varia-
ble resultado principal de la fase de
mantenimiento (11 vs. 21% en muer-
te, duplicación de creatinina basal,
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